Incannex Healthcare Inc. (IXHL): Cash & Equivalents
$67.71M
As of 2026-06-30
$68.27M
As of 2026-09-30
+45.2%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $67.71M | +350.2% | 2026-09-25, Balance as of period end |
| 2025-06-30 | $15.04M | +156.7% | 2026-09-25, Balance as of period end |
| 2024-06-30 | $5.86M | -73.5% | 2025-09-29, Balance as of period end |
| 2023-06-30 | $22.12M | n/a | 2024-09-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | $67.71M | +350.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $251.3K | -18.3% |
Compare IXHL, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗